Trial Profile
A phase II trial of busulfan, melphalan, and fludarabine with peri-transplant palifermin, followed by a T-cell depleted hematopoietic stem cell transplant from HLA [human leukocyte antigen] matched or mismatched related or unrelated donors in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Palifermin (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Stomatitis
- Focus Therapeutic Use
- 21 Oct 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2020 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 04 Mar 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.